Loading clinical trials...

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

NCT05318976•Inmune Bio, Inc.

View on ClinicalTrials.gov

Summary

The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with early ADi.

Detailed Description

This trial is a randomized clinical study using XPro1595 to treat patients with Early Alzheimer's Disease with biomarkers of inflammation (ADi). Early ADi patients are defined as patients with Mild Alzheimer's Disease or Mild Cognitive Impairment (MCI) with a biomarker of inflammation.

Eligibility

Age

50 - 85 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•The screening window for this trial is 45 days.
•To be eligible for study entry, patients must satisfy all of the following criteria:
•Adult patients 50 years to ≤ 85 years of age at the time of consent;
•Meets the diagnostic criteria of MCI of probable Alzheimer's disease (Jack et al. 2018; NIA-AA) or mild dementia as clinically described in McKhann, (2011) and corresponding to stages 3 or 4 of the revised AD staging system (Jack, 2018). (NIA-AA);
•Amyloid positive (documented in medical history or assessed during screening through blood test);
•Either currently or previously (in pre-AD condition) literate and capable of reading, writing, and communicating effectively with others;
•Residence in an assisted living is allowed as is personal assistances provided in the home, however at time of enrollment participant must be able to perform most ADL with minimal assistance, and participant must be permitted sufficient independence to allow assessment of change in ADL;
•Has a study partner for the duration of the trial who either lives in the same household or interacts with the patient at least 4 hours per day and on at least 4 days per week, who is knowledgeable about the patient's daytime and night-time behaviors and who can be available to attend all clinic visits in person at which caregiver assessments are performed.

Exclusion Criteria

•Patients will be excluded from the study if 1 or more of the following criteria are applicable:
•Have any contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (e.g., in-skull and cardiac devices other than those approved as safe for use in MRI scanners);
•Receives considerable help to carry out basic ADL living either in the home or as a resident in a nursing home or similar facility;
•Lifetime history of a major psychiatric disorder including schizophrenia and bipolar disorder. Major depressive disorder that has resulted in 2 or more hospitalizations in a lifetime. Major depressive episode during the past 5 years that is judged by the clinical team unlikely to have been part of Alzheimer's prodrome. History of suicidality.
•History of substance abuse within 12 months; use of cannabis or cannabis products within 6 months of consent;
•Enrolled in another clinical trial where patients receive treatment with an investigational drug or treatment device or have had previous treatment with any investigational medicinal product within 60 days or 5 half-lives (whichever is longer) prior to study drug treatment;
•A prior organ or stem cell transplant;
•Seated blood pressure of ≥ 165/105 mmHg at Screening.

Locations (41)

INmune Bio Investigational Site

Darlinghurst, New South Wales, Australia

INmune Bio Investigational Site

Macquarie Park, New South Wales, Australia

INmune Bio Investigational Site

Adelaide, South Australia, Australia

INmune Bio Investigational Site

Box Hill, Victoria, Australia

INmune Bio Investigational Site

Carlton, Victoria, Australia

INmune Bio Investigational Site

Ivanhoe, Victoria, Australia

INmune Bio Investigational Site

Parkville, Victoria, Australia

INmune Bio Investigational Site

Nedlands, Western Australia, Australia

INmune Bio Investigational Site

Kelowna, Canada

INmune Bio Investigational Site

Ottawa, Canada

Key Dates

Start Date

February 28, 2022

Primary Completion Date

May 12, 2025

Completion Date

May 12, 2025

Last Updated

August 17, 2025

Enrollment

208

ACTUAL participants

Conditions

Alzheimer DiseaseDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersMild Cognitive Impairment

Interventions

XPro1595

DRUG

Placebo

DRUG

Sponsors

Lead Sponsor

Inmune Bio, Inc.

Related Studies

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions